We are looking for individuals or their caregivers with stage 3 or 4 melanoma and the BRAF mutation who are currently being treated with or were recently treated with either of the following combination treatment regimens to participate in a research survey.
Tafinlar (dabrafenib) + Mekinist (trametinib) or
Zelboraf (vemurafenib) + Cotellic (cobimetinib)
The survey will take ~ 45 minutes and individuals will be compensated $100 for their time. If you meet these criteria and are would like to participate please email@example.com.
CH Weaver MD CEO
Copyright © 2018 CancerConnect. All Rights Reserved.